PsiOxus, the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first time that a tumor-specific virus containing four different therapeutic transgenes has been administered to cancer patients. Source: PsiOxus press release 5/3/2020